These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18381410)

  • 1. Enhancing poxvirus oncolytic effects through increased spread and immune evasion.
    Kirn DH; Wang Y; Liang W; Contag CH; Thorne SH
    Cancer Res; 2008 Apr; 68(7):2071-5. PubMed ID: 18381410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2.
    Guo ZS; Naik A; O'Malley ME; Popovic P; Demarco R; Hu Y; Yin X; Yang S; Zeh HJ; Moss B; Lotze MT; Bartlett DL
    Cancer Res; 2005 Nov; 65(21):9991-8. PubMed ID: 16267024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
    Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
    Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.
    Bell E; Shamim M; Whitbeck JC; Sfyroera G; Lambris JD; Isaacs SN
    Virology; 2004 Aug; 325(2):425-31. PubMed ID: 15246280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular enveloped vaccinia virus escapes neutralization.
    Ichihashi Y
    Virology; 1996 Mar; 217(2):478-85. PubMed ID: 8610439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.
    Sampath P; Li J; Hou W; Chen H; Bartlett DL; Thorne SH
    Mol Ther; 2013 Mar; 21(3):620-8. PubMed ID: 23229093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.
    Thorne SH; Contag CH
    Gene Ther; 2008 May; 15(10):753-8. PubMed ID: 18356814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice.
    Ganesh S; Gonzalez Edick M; Idamakanti N; Abramova M; Vanroey M; Robinson M; Yun CO; Jooss K
    Cancer Res; 2007 May; 67(9):4399-407. PubMed ID: 17483354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antitumor effects of immune cell-viral biotherapy.
    Thorne SH; Negrin RS; Contag CH
    Science; 2006 Mar; 311(5768):1780-4. PubMed ID: 16556847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation oncolytic vaccinia vectors.
    Thorne SH
    Methods Mol Biol; 2012; 797():205-15. PubMed ID: 21948478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.
    Zhang Q; Yu YA; Wang E; Chen N; Danner RL; Munson PJ; Marincola FM; Szalay AA
    Cancer Res; 2007 Oct; 67(20):10038-46. PubMed ID: 17942938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent.
    Gentschev I; Stritzker J; Hofmann E; Weibel S; Yu YA; Chen N; Zhang Q; Bullerdiek J; Nolte I; Szalay AA
    Cancer Gene Ther; 2009 Apr; 16(4):320-8. PubMed ID: 18949014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic vaccinia virus: from bedside to benchtop and back.
    Thorne SH
    Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1.
    Huang B; Sikorski R; Kirn DH; Thorne SH
    Gene Ther; 2011 Feb; 18(2):164-72. PubMed ID: 20739958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
    Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
    Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.
    Thirunavukarasu P; Sathaiah M; Gorry MC; O'Malley ME; Ravindranathan R; Austin F; Thorne SH; Guo ZS; Bartlett DL
    Mol Ther; 2013 May; 21(5):1024-33. PubMed ID: 23439499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and testing of novel oncolytic vaccinia strains.
    Thorne SH
    Methods Mol Biol; 2009; 542():635-47. PubMed ID: 19565925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody neutralization of the extracellular enveloped form of vaccinia virus.
    Law M; Smith GL
    Virology; 2001 Feb; 280(1):132-42. PubMed ID: 11162827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The exit of vaccinia virus from infected cells.
    Smith GL; Law M
    Virus Res; 2004 Dec; 106(2):189-97. PubMed ID: 15567497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy.
    Yun CO
    Curr Opin Mol Ther; 2008 Aug; 10(4):356-61. PubMed ID: 18683100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.